Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

477.65 -11.66 (-2.38%)
Streaming Delayed Price Updated: 11:32 AM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Value Investing Case Study ↗
United Therapeutics (UTHR) presents a compelling value investment case with strong profitability, a debt-free balance sheet, and a valuation discounted relative to its biotech sector peers. 
Via Chartmill
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Caviar Cruise Quality Investment ↗
United Therapeutics (UTHR) excels as a Caviar Cruise quality stock with strong growth, high profitability, a debt-free balance sheet, and exceptional returns on capital. 
Via Chartmill
News headline image
2 Mooning Stocks on Our Buy List and 1 That Underwhelm
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Presents a Compelling Value Investment Case ↗
United Therapeutics (UTHR) offers strong value with a low P/E ratio, zero debt, and high profitability. This biotech stock presents a compelling opportunity for value investors. 
Via Chartmill
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
3 Reasons Investors Love United Therapeutics (UTHR)
United Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 44.4%, reaching $448.91 per share. This performance may have investors wondering how to... 
Via StockStory
News headline image
Is United Therapeutics Corp Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for United Therapeutics ↗
 
Via Benzinga
News headline image
My Top Vanguard Index ETF Pick for 2026 ↗
This ETF has underperformed the S&P 500 lately, but I think that will change. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
The 5 Most Interesting Analyst Questions From United Therapeutics’s Q3 Earnings Call
United Therapeutics delivered a quarter that was well received by the market despite missing revenue expectations, as operational progress and clinical milestones took center stage. Management credited... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
If You Invested $100 In United Therapeutics Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Offers Affordable Growth with Strong Profitability ↗
United Therapeutics offers strong growth, high profitability, and a robust balance sheet, yet trades at a significant discount to the biotech industry. A top pick for affordable growth. 
Via Chartmill
News headline image
United Therapeutics (UTHR) Earnings Transcript ↗
United Therapeutics (UTHR) Earnings Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls. 
Via Investor's Business Daily
News headline image
UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per... 
Via StockStory
News headline image
Why Is United Therapeutics (UTHR) Stock Soaring Today
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 11.7% in the afternoon session after the company reported record third-quarter financial results and announced positive outcomes... 
Via StockStory
News headline image
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗
A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100... 
Via Benzinga
Topics Economy Stocks
News headline image
United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short ↗
Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso. 
Via Investor's Business Daily
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Reports Q3 2025 Earnings: Revenue Misses, EPS Beats Estimates ↗
United Therapeutics posts record Q3 2025 revenue of $799.5M, driven by strong Tyvaso growth. The company beat EPS estimates but slightly missed on revenue. 
Via Chartmill
News headline image
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per... 
Via StockStory
News headline image
A Peek at United Therapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
If You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Meets Key Peter Lynch Investment Criteria ↗
United Therapeutics (UTHR) aligns with Peter Lynch's investment strategy, showing strong earnings growth, a fair PEG ratio, and a debt-free balance sheet for long-term value. 
Via Chartmill
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Prime Value Investment Candidate ↗
United Therapeutics (UTHR) is a strong value stock with a low P/E ratio, zero debt, high profitability, and solid growth, making it an undervalued biotech pick. 
Via Chartmill
News headline image
1 Value Stock for Long-Term Investors and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.